PATENT CLAIM ANALYSIS

Application Number: 16043994
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["435", "007920"]

Abstract:
An object of the present invention is to provide a novel Pca determination method and a Pca malignancy determination method. The present invention is an invention relating to a “prostate carcinoma determination method, including determining the ratio of the amount of free prostate specific antigen, which has a glycan in which the terminal sialic acid residue of the glycan is α(2,3)-linked to a second galactose residue from the terminal of the glycan, to the amount of free PSA in a biological sample, and then determining that prostate carcinoma is developed or the probability of developing prostate carcinoma is high in the case where the ratio is 40% or higher.”

Claim (Index 17):
The postate carcinoma determination method according to  claim 6 , further comprising:\n determining that prostate carcinoma is developed or the probability of developing prostate carcinoma is high in the case where the ratio of the amount of \u03b1(2,3) free PSA to the amount of free PSA is 40% or higher; and determining that the probability of high malignancy of prostate carcinoma is high in the case where the ratio is 47% or higher.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 95.0
- Lexical Diversity: 1.93651
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14432902', '13505280', '15005964', '14203438', '10530972']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6098236545788389
- 35 USC 102 Novelty (BERT): 0.555064227977115
- Combined Prediction Score: 0.6043477119186665
- Mean Citation Score: 304.047912
- Max Citation Score: 460.5301
- Similarity Product: 331.12354913178683

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test